NCT01085318已完成4 期
A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- EMD Serono
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months
研究概览
简要总结
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects, 18-65 years of age, inclusive, at the time of informed consent signature
- •RRMS diagnosed according to the McDonald criteria, treatment naïve or currently using any of the FDA-approved DMDs (excluding natalizumab (Tysabri®), mitoxantrone or Rebif®)
- •Have a disease duration of up to twenty years
- •Be willing and able to comply with the study procedures for the duration of the trial
- •Have given written informed consent and signed Health Insurance Portability and Accountability Act (HIPAA) Authorization before any study- related activities are carried out
- •Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either:
- •The following inclusion criteria must be fulfilled by the Healthy Control subjects:
- •Male and female subjects, 18-65 years of age, inclusive, at the time of informed consent signature
- •Be willing and able to comply with the study procedures for the duration of the trial
- •Have given written informed consent and signed Health Insurance Portability and Accountability Act (HIPAA) Authorization before any study- related activities are carried out
- •Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either:
排除标准
- •Have received treatment within three months prior to Screening with interferon-beta-1a (Rebif®), IVIG or plasmapheresis
- •Have received treatment within thirty days prior to screening with immunosuppressant agents (e.g. including but not limited to mitoxantrone, cyclophosphamide, cladribine, fludarabine, cyclosporine or total body irradiation) or any other concomitant immunomodulatory therapies (e.g., azathioprine, methotrexate, CellCept®, natalizumab, alemtuzumab/Campath and other immunomodulators/monoclonal agents)
- •Have had a relapse within thirty days prior to the Screening Visit
- •Have received steroid treatment within thirty days prior to the initial MRI scan date at Study Day 1
- •Have inadequate liver function, defined by a alanine aminotransferase (ALT) > 2.5x upper limit of normal (ULN), or alkaline phosphatase > 2.5x ULN, or total bilirubin > 1.5x ULN
- •Have inadequate bone marrow reserve, defined as a total white blood cell count < 3.0x 109/L, platelet count < 75x109/L, hemoglobin < 100g/L
- •Have complete transverse myelitis or simultaneous-onset bilateral optic neuritis
- •Have a history of alcohol or drug abuse
- •Have thyroid dysfunction
- •Have moderate to severe renal impairment
- •Have a major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol
- •Have a history of seizures not adequately controlled by treatment
- •Have serious or acute cardiac disease, such as uncontrolled dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure
- •Have, in the opinion of the investigator, any visual, physical or cognitive impairment that would preclude the subject from complying with the study protocol
- •Have a known hypersensitivity or allergy to interferon-beta or any of the excipients
- •Have received an investigational drug or experimental procedure within the past thirty days
- •Are pregnant or attempting to conceive
- •The following exclusion criteria must be fulfilled by the Healthy Control subjects:
- •Have met any of the above noted criteria
研究组 & 干预措施
Arm 1 MS Patients
Active Comparator
Rebif 44 tiw
干预措施: Rebif (Drug)
结局指标
主要结局
Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Increasing (Indicative of Remyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR) From Baseline to 6 Months
时间窗: Baseline to Month 6
To characterize the effect of Rebif on remyelination using VW-MTR dynamic mapping of NABT in subjects ith RRMS over 6 months of treatment compared to a group of healthy Control (HC).
次要结局
- Change in Volume (in Millimeters Cubed) of Normal Appearing Brain Tissue (NABT) With Decreasing (Indicative of Demyelination) Voxel-wise Magnetization Transfer Ratio (VW-MTR)From Baseline to 6 Months(Baseline to Month 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisRelapsing-remitting Multiple SclerosisNCT00078338EMD Serono764
已完成
不适用
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and LymphocytesRelapsing-Remitting Multiple SclerosisNCT03284970EMD Serono Research & Development Institute, Inc.34
已完成
4 期
Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™Relapsing Multiple SclerosisClinically Isolated SyndromeNCT02254304Merck KGaA, Darmstadt, Germany106
已完成
3 期
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00441103Merck KGaA, Darmstadt, Germany180
已完成
不适用
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyMultiple Sclerosis, Relapsing-RemittingNCT01141751Merck KGaA, Darmstadt, Germany334